Drug
Macupatide clinical trials
Also written LY3532226.
- studies test it
- 8
- open now
- 3
- in phase 3
- 0
- first study started
- 2021
Keep track of what changes. Save the macupatide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
8 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Eloralintide (4) · Dulaglutide (1) · Mazdutide (1) · Tirzepatide (1) · Naperiglipron (1)
Studies
Open first, then newest update. How each study uses macupatide is read from its arms, and is right about nine times in ten.
Testing it · 8
- A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightRecruitingPhase 2Eli Lilly and CompanyNCT07589608Written as Macupatide
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRecruitingPhase 2Eli Lilly and CompanyNCT06143956Written as LY3532226
- A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 DiabetesNot yet recruitingPhase 1Eli Lilly and CompanyNCT07765511Written as Macupatide
- A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesActive, not recruitingPhase 2Eli Lilly and CompanyNCT07215559Written as Macupatide
- A Study of LY3532226 in Participants With ObesityCompletedPhase 1Eli Lilly and CompanyNCT06557356Written as LY3532226
- A Study of LY3532226 in Participants With Type 2 Diabetes MellitusCompletedPhase 1Eli Lilly and CompanyNCT05407961Written as LY3532226
- A Study of LY3532226 in Participants With Type 1 Diabetes MellitusCompletedPhase 1Eli Lilly and CompanyNCT05887999Written as LY3532226
- A Study of LY3532226 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04923269Written as LY3532226
Codes
What other systems call macupatide · ClinicalTrials.gg INT018625
- UNII (FDA) YWF427CA5DMACUPATIDEOne source FDA
- NCI Thesaurus C213416MacupatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | YWF427CA5D | MACUPATIDE | One source FDA |
| NCI Thesaurus | C213416 | Macupatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.